NO328106B1 - Fremgangsmate for rensing av 20(S)-camptothecin - Google Patents
Fremgangsmate for rensing av 20(S)-camptothecin Download PDFInfo
- Publication number
- NO328106B1 NO328106B1 NO20033614A NO20033614A NO328106B1 NO 328106 B1 NO328106 B1 NO 328106B1 NO 20033614 A NO20033614 A NO 20033614A NO 20033614 A NO20033614 A NO 20033614A NO 328106 B1 NO328106 B1 NO 328106B1
- Authority
- NO
- Norway
- Prior art keywords
- camptothecin
- purifying
- vinyl
- crystals
- formula
- Prior art date
Links
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 title claims abstract description 51
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 title claims abstract description 47
- 238000000034 method Methods 0.000 title claims abstract description 20
- 229940127093 camptothecin Drugs 0.000 claims abstract description 53
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000000203 mixture Substances 0.000 claims abstract description 17
- 239000013078 crystal Substances 0.000 claims abstract description 15
- 239000003054 catalyst Substances 0.000 claims abstract description 11
- 229910052723 transition metal Inorganic materials 0.000 claims abstract description 10
- 150000003624 transition metals Chemical class 0.000 claims abstract description 10
- 239000008346 aqueous phase Substances 0.000 claims abstract description 8
- 239000003880 polar aprotic solvent Substances 0.000 claims abstract description 8
- -1 carboxylate salt Chemical class 0.000 claims abstract description 7
- 150000002596 lactones Chemical group 0.000 claims abstract description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 16
- 239000007858 starting material Substances 0.000 claims description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 12
- 229920002554 vinyl polymer Polymers 0.000 claims description 9
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 229910052763 palladium Inorganic materials 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 150000007513 acids Chemical class 0.000 claims description 3
- GUVUOGQBMYCBQP-UHFFFAOYSA-N dmpu Chemical compound CN1CCCN(C)C1=O GUVUOGQBMYCBQP-UHFFFAOYSA-N 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- CYSGHNMQYZDMIA-UHFFFAOYSA-N 1,3-Dimethyl-2-imidazolidinon Chemical compound CN1CCN(C)C1=O CYSGHNMQYZDMIA-UHFFFAOYSA-N 0.000 claims description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 2
- 239000000010 aprotic solvent Substances 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- ZCOGQSHZVSZAHH-UHFFFAOYSA-N n,n-dimethylaziridine-1-carboxamide Chemical compound CN(C)C(=O)N1CC1 ZCOGQSHZVSZAHH-UHFFFAOYSA-N 0.000 claims description 2
- 229910017604 nitric acid Inorganic materials 0.000 claims description 2
- 235000011007 phosphoric acid Nutrition 0.000 claims description 2
- 235000011149 sulphuric acid Nutrition 0.000 claims description 2
- 235000011054 acetic acid Nutrition 0.000 claims 1
- VGGNVBNNVSIGKG-UHFFFAOYSA-N n,n,2-trimethylaziridine-1-carboxamide Chemical compound CC1CN1C(=O)N(C)C VGGNVBNNVSIGKG-UHFFFAOYSA-N 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000001816 cooling Methods 0.000 abstract 1
- 238000010438 heat treatment Methods 0.000 abstract 1
- 230000001131 transforming effect Effects 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 241000060390 Nothapodytes nimmoniana Species 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000005984 hydrogenation reaction Methods 0.000 description 4
- 229910000000 metal hydroxide Inorganic materials 0.000 description 4
- 150000004692 metal hydroxides Chemical class 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 230000020477 pH reduction Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- HAWSQZCWOQZXHI-FQEVSTJZSA-N 10-Hydroxycamptothecin Chemical compound C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-FQEVSTJZSA-N 0.000 description 1
- HAWSQZCWOQZXHI-UHFFFAOYSA-N CPT-OH Natural products C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-UHFFFAOYSA-N 0.000 description 1
- 241000759905 Camptotheca acuminata Species 0.000 description 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000209018 Nyssaceae Species 0.000 description 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 229910000272 alkali metal oxide Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 125000000686 lactone group Chemical group 0.000 description 1
- 238000007273 lactonization reaction Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 125000002348 vinylic group Chemical group 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003799 water insoluble solvent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10106969A DE10106969C1 (de) | 2001-02-15 | 2001-02-15 | Verfahren zur Reinigung und zur Herstellung von 20(S)-Camptothecin |
PCT/EP2002/001375 WO2002064597A2 (de) | 2001-02-15 | 2002-02-09 | Verfahren zur reinigung von 20(s)-camptothecin |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20033614D0 NO20033614D0 (no) | 2003-08-14 |
NO20033614L NO20033614L (no) | 2003-08-14 |
NO328106B1 true NO328106B1 (no) | 2009-12-07 |
Family
ID=7674093
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20033614A NO328106B1 (no) | 2001-02-15 | 2003-08-14 | Fremgangsmate for rensing av 20(S)-camptothecin |
Country Status (27)
Country | Link |
---|---|
EP (1) | EP1362051B1 (xx) |
JP (1) | JP4467884B2 (xx) |
KR (1) | KR100813087B1 (xx) |
CN (1) | CN1228340C (xx) |
AT (1) | ATE301124T1 (xx) |
AU (1) | AU2002244711B2 (xx) |
BG (1) | BG108064A (xx) |
BR (1) | BR0207261A (xx) |
CA (1) | CA2435372C (xx) |
CZ (1) | CZ300671B6 (xx) |
DE (2) | DE10106969C1 (xx) |
EA (1) | EA005618B1 (xx) |
EE (1) | EE05131B1 (xx) |
ES (1) | ES2246389T3 (xx) |
HK (1) | HK1064092A1 (xx) |
HR (1) | HRP20030654A2 (xx) |
HU (1) | HUP0303030A3 (xx) |
IL (2) | IL157148A0 (xx) |
MX (1) | MXPA03007194A (xx) |
NO (1) | NO328106B1 (xx) |
NZ (1) | NZ528039A (xx) |
PL (1) | PL202135B1 (xx) |
RS (1) | RS50496B (xx) |
SK (1) | SK10192003A3 (xx) |
UA (1) | UA74874C2 (xx) |
WO (1) | WO2002064597A2 (xx) |
ZA (1) | ZA200305364B (xx) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI396690B (zh) * | 2006-04-27 | 2013-05-21 | Yakult Honsha Kk | 喜樹鹼衍生物的製造方法 |
KR101600114B1 (ko) * | 2008-05-29 | 2016-03-04 | 니혼 마이크로바이오팜 가부시키가이샤 | 캠토테신 유도체의 제조 방법 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5527913A (en) * | 1993-02-25 | 1996-06-18 | The Stehlin Foundation For Cancer Research | Methods for purifying camptothecin compounds |
-
2001
- 2001-02-15 DE DE10106969A patent/DE10106969C1/de not_active Expired - Fee Related
-
2002
- 2002-02-09 RS YUP-614/03A patent/RS50496B/sr unknown
- 2002-02-09 CZ CZ20032211A patent/CZ300671B6/cs not_active IP Right Cessation
- 2002-02-09 WO PCT/EP2002/001375 patent/WO2002064597A2/de active IP Right Grant
- 2002-02-09 EP EP02712902A patent/EP1362051B1/de not_active Expired - Lifetime
- 2002-02-09 EA EA200300837A patent/EA005618B1/ru not_active IP Right Cessation
- 2002-02-09 HU HU0303030A patent/HUP0303030A3/hu unknown
- 2002-02-09 BR BR0207261-0A patent/BR0207261A/pt not_active Expired - Fee Related
- 2002-02-09 CA CA2435372A patent/CA2435372C/en not_active Expired - Lifetime
- 2002-02-09 NZ NZ528039A patent/NZ528039A/en unknown
- 2002-02-09 IL IL15714802A patent/IL157148A0/xx active IP Right Grant
- 2002-02-09 KR KR1020037010605A patent/KR100813087B1/ko not_active IP Right Cessation
- 2002-02-09 AU AU2002244711A patent/AU2002244711B2/en not_active Ceased
- 2002-02-09 JP JP2002564528A patent/JP4467884B2/ja not_active Expired - Lifetime
- 2002-02-09 SK SK1019-2003A patent/SK10192003A3/sk unknown
- 2002-02-09 DE DE50203824T patent/DE50203824D1/de not_active Expired - Lifetime
- 2002-02-09 ES ES02712902T patent/ES2246389T3/es not_active Expired - Lifetime
- 2002-02-09 EE EEP200300389A patent/EE05131B1/xx not_active IP Right Cessation
- 2002-02-09 CN CNB028049918A patent/CN1228340C/zh not_active Expired - Fee Related
- 2002-02-09 AT AT02712902T patent/ATE301124T1/de active
- 2002-02-09 PL PL362128A patent/PL202135B1/pl not_active IP Right Cessation
- 2002-02-09 MX MXPA03007194A patent/MXPA03007194A/es active IP Right Grant
- 2002-09-02 UA UA2003098461A patent/UA74874C2/uk unknown
-
2003
- 2003-07-11 ZA ZA200305364A patent/ZA200305364B/en unknown
- 2003-07-29 IL IL157148A patent/IL157148A/en not_active IP Right Cessation
- 2003-08-06 BG BG108064A patent/BG108064A/bg active Pending
- 2003-08-13 HR HR20030654A patent/HRP20030654A2/hr not_active Application Discontinuation
- 2003-08-14 NO NO20033614A patent/NO328106B1/no not_active IP Right Cessation
-
2004
- 2004-09-08 HK HK04106806A patent/HK1064092A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7223863B2 (en) | Process for preparing Tadalafil and its intermediate | |
JP5166878B2 (ja) | 臭化水素酸ガランタミンの製造方法 | |
NO172577B (no) | Fremgangsmaate og mellomprodukter ved fremstilling av substituerte indolinonderivater | |
CA2859281A1 (en) | Process for the preparation of (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid esters | |
NO328106B1 (no) | Fremgangsmate for rensing av 20(S)-camptothecin | |
JP5192707B2 (ja) | ミルタザピンの製造方法 | |
CN105061428B (zh) | 一种精制他达拉非的方法 | |
US6476225B2 (en) | Process for purifying 20(S)-camptothecin | |
KR20180116371A (ko) | 4-알콕시-3-히드록시피콜린산의 제조 방법 | |
CA2576862C (en) | A process for producing pure form of 2-methyl-4-(4-methyl-1-piperazinyl)-10h-thieno[2,3-b][1,5]benzodiazepine | |
JP2011522042A (ja) | タダラフィルの製造方法 | |
JP2002524450A5 (xx) | ||
CN113387959A (zh) | 一种噻吩并[3,2-c]吡啶-6-羧酸甲酯的合成方法 | |
CN117700411A (zh) | 一种帕利哌酮关键中间体的合成方法 | |
DK154504B (da) | Fremgangsmaade til fremstilling af benzotiazindioxyd samt mellemprodukt til anvendelse ved udoevelse af fremgangsmaaden | |
CN104277036A (zh) | 一种(4aS,7aS)-八氢-1H-吡咯并[3,4-b]吡啶的纯化方法 | |
WO2012032531A1 (en) | Process for the manufacture of irinotecan hydrochloride by total synthesis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |